JP2011506328A5 - - Google Patents

Download PDF

Info

Publication number
JP2011506328A5
JP2011506328A5 JP2010537016A JP2010537016A JP2011506328A5 JP 2011506328 A5 JP2011506328 A5 JP 2011506328A5 JP 2010537016 A JP2010537016 A JP 2010537016A JP 2010537016 A JP2010537016 A JP 2010537016A JP 2011506328 A5 JP2011506328 A5 JP 2011506328A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
peptide
composition according
seq
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010537016A
Other languages
English (en)
Japanese (ja)
Other versions
JP5520230B2 (ja
JP2011506328A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/085280 external-priority patent/WO2009076105A2/en
Publication of JP2011506328A publication Critical patent/JP2011506328A/ja
Publication of JP2011506328A5 publication Critical patent/JP2011506328A5/ja
Application granted granted Critical
Publication of JP5520230B2 publication Critical patent/JP5520230B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010537016A 2007-12-05 2008-12-02 内在化ペプチドに連結された薬剤と抗炎症剤との共投与 Expired - Fee Related JP5520230B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99267807P 2007-12-05 2007-12-05
US60/992,678 2007-12-05
PCT/US2008/085280 WO2009076105A2 (en) 2007-12-05 2008-12-02 Co-administration of an agent linked to an internalization peptide with an anti-inflammatory

Publications (3)

Publication Number Publication Date
JP2011506328A JP2011506328A (ja) 2011-03-03
JP2011506328A5 true JP2011506328A5 (https=) 2012-02-16
JP5520230B2 JP5520230B2 (ja) 2014-06-11

Family

ID=40756064

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010537016A Expired - Fee Related JP5520230B2 (ja) 2007-12-05 2008-12-02 内在化ペプチドに連結された薬剤と抗炎症剤との共投与

Country Status (14)

Country Link
US (1) US8080518B2 (https=)
EP (1) EP2229185B8 (https=)
JP (1) JP5520230B2 (https=)
CN (1) CN101970011B (https=)
AU (1) AU2008335490B2 (https=)
BR (1) BRPI0820912B1 (https=)
DK (1) DK2229185T3 (https=)
ES (1) ES2555524T3 (https=)
HR (1) HRP20151312T1 (https=)
HU (1) HUE027216T2 (https=)
PL (1) PL2229185T3 (https=)
PT (1) PT2229185E (https=)
SI (1) SI2229185T1 (https=)
WO (1) WO2009076105A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
DK2043671T3 (da) * 2006-07-11 2020-06-15 Nono Inc Peptid og sammensætning deraf til anvendelse ved behandling af slagtilfælde med feber
US8008253B2 (en) * 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
DK2307035T3 (da) * 2008-05-16 2014-01-20 Nono Inc Anvendelse af en PSD-95 inhibitor ved behandlingen af epilepsi
CA2739416C (en) 2008-09-03 2017-10-31 Arbor Vita Corporation Agents and methods for treatment of pain
EP3682895A1 (en) 2009-06-10 2020-07-22 NoNO Inc. Co-administration of an agent linked to a tat-internalization peptide with a mast cell degranulation inhibitor
WO2010144721A2 (en) 2009-06-10 2010-12-16 Arbor Vita Corporation Model systems and treatment regimes for treatment of neurological disease
US9301999B2 (en) 2009-09-28 2016-04-05 Duke University Peptide, adjuvants, vaccines, and methods of use
JP2013527834A (ja) * 2010-03-29 2013-07-04 マサチューセッツ インスティテュート オブ テクノロジー 抗炎症因子
AU2011279703B2 (en) * 2010-06-10 2016-07-07 Indiana University Research And Technology Corporation Materials and method for suppressing inflamatory and neuropathic pain
EP2616094B1 (en) * 2010-08-12 2017-11-08 NoNO Inc. Treatment of penetrative injury to the brain
JP6084207B2 (ja) * 2011-05-13 2017-02-22 ケベンハウンス ウニヴェルジテート(ユニバーシティ オブ コペンハーゲン)Koebenhavns Universitet(University Of Copenhagen) 虚血性脳損傷及び疼痛治療用の効率的な神経保護剤としてのpsd−95の高親和性二量体阻害剤
ES2912042T3 (es) 2011-06-24 2022-05-24 Nono Inc Terapia de combinación para isquemia
US9730921B2 (en) 2012-03-27 2017-08-15 Duke University Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
CA2892965C (en) * 2012-11-28 2021-06-01 Nono Inc. Lyophilized formulation of tat-nr2b9c
US9783586B2 (en) * 2013-03-15 2017-10-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the linear ubiquitin chain assembly complex (LUBAC) and related methods
US20140349944A1 (en) * 2013-05-23 2014-11-27 Musc Foundation For Research Development Chaperone-based integrin inhibitors for the treatment of cancer and inflammatory diseases
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
EP2946767B1 (en) 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
EP3050557A1 (en) 2014-05-23 2016-08-03 Ares Trading S.A. Liquid pharmaceutical composition
WO2016049280A1 (en) * 2014-09-24 2016-03-31 Memorial Sloan Kettering Cancer Center mTORC1 MODULATION
KR102545825B1 (ko) * 2017-09-30 2023-06-22 바이오셀즈(베이징) 바이오테크 코., 엘티디. 흥분성 신경 독성 관련 손상 치료를 위한 펩타이드 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1159418A2 (en) * 1998-12-11 2001-12-05 Biomira Inc. Muc-1 antagonists and methods of treating immune disorders
US20040226056A1 (en) 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
US20060148711A1 (en) * 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
DE60026313D1 (de) 1999-07-23 2006-04-27 Uutech Ltd Sensibilisierung von roten blutkörperchen gegenüber ultraschall durch einwirkung eines elektrischen feldes
CA2381425A1 (en) 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US6864355B1 (en) * 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
US20020032154A1 (en) * 2000-06-07 2002-03-14 Peyman John A. Interferon-suppressing placental lactogen peptides
US6887687B2 (en) 2001-07-30 2005-05-03 Immunex Corporation Nucleic acids encoding human ataxin-1-like polypeptide IMX97018
EP1601380A1 (en) * 2003-02-13 2005-12-07 Licentia OY Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
US7947645B2 (en) * 2004-09-02 2011-05-24 Cognosci, Inc. APO E analogs and methods for their use
US7151084B2 (en) * 2004-12-27 2006-12-19 Miller Landon C G Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes
WO2009006611A1 (en) * 2007-07-03 2009-01-08 Arbor Vita Corporation Small molecule inhibitors of pdz interactions
CN101842107B (zh) * 2007-07-26 2014-04-23 雷文斯治疗公司 抗微生物肽,组合物和使用方法
ES2328776B1 (es) * 2007-11-19 2010-07-06 Proyecto De Biomedicina Cima S.L. Peptidos con capacidad para unirse a escurfina y aplicaciones.
EP3682895A1 (en) 2009-06-10 2020-07-22 NoNO Inc. Co-administration of an agent linked to a tat-internalization peptide with a mast cell degranulation inhibitor

Similar Documents

Publication Publication Date Title
JP2011506328A5 (https=)
HRP20151312T1 (hr) Ko-administracija sredstva vezanog na tat internalizacijski peptid s protuupalnim sredstvom
JP2012530060A5 (https=)
US8933013B2 (en) Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
JP2014527040A5 (https=)
Tang et al. Tanshinone IIA ameliorates bleomycin-induced pulmonary fibrosis and inhibits transforming growth factor-beta-β–dependent epithelial to mesenchymal transition
Lei et al. The novel Nrf2 activator CDDO‐EA attenuates cerebral ischemic injury by promoting microglia/macrophage polarization toward M2 phenotype in mice
JP2012176978A5 (https=)
Goldsmith et al. Intestinal epithelial cell–derived μ-opioid signaling protects against ischemia reperfusion injury through PI3K Signaling
JP2005506370A5 (https=)
JP2015057436A5 (https=)
EA200971130A1 (ru) Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
NZ600790A (en) Combination therapy for copd
WO2011047097A3 (en) Inhibition of trem receptor signaling with peptide variants
AR079706A1 (es) Composiciones, metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis y uso
JP2014516942A5 (https=)
JP2010536714A5 (https=)
JP2011528334A5 (https=)
Hill et al. Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study
WO2009047826A2 (en) Pharmaceutical composition comprising sucralphate and mesalazine
Urakov et al. Inflammation, infiltration, necrosis, abscess and Nicolau syndrome after injection of nonsteroidal anti-inflammatory drugs: What is the reason?
Hawley et al. Switching stable patients with schizophrenia from depot and oral antipsychotics to long‐acting injectable risperidone: reasons for switching and safety
CN103585153B (zh) Caesanines D在治疗和预防肾纤维化药物中的应用
WO2006043260A3 (en) Orally effective cannabinoid analogs
CN103599095B (zh) Hippolachnin A在治疗和预防肾纤维化药物中的应用